Compremium's revolutionary device on board a NASA mission

Compremium’s revolutionary device on board a NASA mission

Bern-based medtech company Compremium has delivered to NASA its pioneering compartment compressibility monitoring system, a significant advance to ensure the health of astronauts during deep space missions.

Rooted in the deep tradition of precision and innovation of Western Switzerland, Compremium is making waves beyond our planet. This medical technology company, renowned for its groundbreaking solutions in the medical field, recently sent its revolutionary Compartmental Compressibility Monitoring System (CPMX1) to NASA.

At the beginning of the year, the Bern-based company achieved a monumental breakthrough by obtaining FDA approval for the CPMX1. A true testament to Swiss innovation, this device is the first of its kind, capable of reliably and non-invasively measuring the compressibility of muscles and tissues in the human body. The system is designed to provide healthcare professionals with objective data related to trauma, emergencies, and chronic diseases. Such precision is crucial for mitigating clinical uncertainties and reducing overtreatment and missed diagnoses.

NASA’s Johnson Space Center in Houston, Texas, will be the first recipient of Compremium’s product line. NASA’s vision for the CPMX1 extends beyond Earth, as the device is slated for use on upcoming deep-space missions to the Moon and Mars. These missions, scheduled to begin in 2024, aim to further investigate fluid movement within the human body under weightless conditions. Compremium’s CPMX1, with its unique capabilities, can detect bodily changes resulting from prolonged exposure to weightlessness, thus playing a vital role in maintaining astronaut health during extended spaceflights.

Revolutionizing Diagnostics (in Space):
The collaboration between NASA and Compremium has a long history, dating back more than twenty years. Dr. Ulrich A. Baumann, Chief Medical Officer of Compremium, initiated this partnership with the development of the Veinpress device, a pioneering tool for the non-invasive measurement of venous pressure in the human body. After rigorous testing, including zero-gravity flights and validation at NASA’s Houston laboratory, the Veinpress device has been operational on the International Space Station since 2018. This revolutionary device paved the way for the creation of the CPMX1.

Beyond its ties with NASA, Compremium continues to foster global collaborations, partnering with leading scientific entities, institutions, and hospitals. Founded by Dr. U. Baumann, the company comprises a diverse team of physicians, engineers, and professionals, all united in their mission to revolutionize diagnostics and improve patient outcomes.

Watch Also: https://www.youtube.com/@TravelsofTheWorld24